State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Beijing 100037, China.
Department of Pathophysiology, Key Laboratory of Cardiovascular Pathophysiology, Harbin Medical University, Harbin 150081, China.
J Immunol Res. 2020 Feb 14;2020:5284728. doi: 10.1155/2020/5284728. eCollection 2020.
Atherosclerosis is a multifactorial chronic inflammatory arterial disease forming the pathological basis of many cardiovascular diseases such as coronary heart disease, heart failure, and stroke. Numerous studies have implicated inflammation as a key player in the initiation and progression of atherosclerosis. Galectin-3 (Gal-3) is a 30 kDa -galactose, highly conserved and widely distributed intracellularly and extracellularly. Gal-3 has been demonstrated in recent years to be a novel inflammatory factor participating in the process of intravascular inflammation, lipid endocytosis, macrophage activation, cellular proliferation, monocyte chemotaxis, and cell adhesion. This review focuses on the role of Gal-3 in atherosclerosis and the mechanism involved and several classical Gal-3 agonists and antagonists in the current studies.
动脉粥样硬化是一种多因素的慢性炎症性动脉疾病,是许多心血管疾病(如冠心病、心力衰竭和中风)的病理基础。大量研究表明炎症是动脉粥样硬化发生和发展的关键因素。半乳糖凝集素-3(Galectin-3,Gal-3)是一种 30kDa 的β-半乳糖,在细胞内和细胞外广泛分布且高度保守。近年来研究表明,Gal-3 是一种新型的炎症因子,参与血管内炎症、脂质内吞、巨噬细胞激活、细胞增殖、单核细胞趋化和细胞黏附过程。本综述重点介绍 Gal-3 在动脉粥样硬化中的作用及其相关机制,以及目前研究中几种经典的 Gal-3 激动剂和拮抗剂。